INTRODUCTION
Cisplatin (cis-dichlorodiammineplatinum II; CDDP), a broad spectrum anticancer agent has severe toxic side effects including nephrotoxicity, gastrointestinal toxicity and hypocalcemia. Nephrotoxicity manifests pathologically, as renal tubular damage which results in elevation of the blood urea nitrogen and serum creatinine levels. ' Hydrating patients markedly diminishes kidney toxicity. Antioxidants and thiol containing compounds, such as sodium thiosulfate, have become part of the treatment regimen in an attempt to alleviate nephrotoxicity. Despite these advances, nephrotoxicity is still a major concern. Similarly, various antiemetics are being used to alleviate emesis at great costs. 4 We can treat the symptoms but still are unable to point out the cause(s) of these toxicities. Although newer compounds are being synthesized with substitutions of various ligands to increase its efficacy and decrease its toxicities. In the process we may learn more about the structural and functional relationship.
Gastrointestinal toxicity in rats is manifest as bloating of the stomach and severe diarrhea as the rats do not have vomiting reflexes. Dogs however, do show vomiting reflexes and diarrhea in response to CDDP treatments. Calcium supplements have been shown to prevent stomach bloating in rats, protect enzyme function and preserve overall organ function by minimizing the disruption of cellular homeostasis initiated by CDDP treatment.
z Present study was undertaken to characterize CDDP-induced changes in the various dehydrogenases involved in the glycolysis process and Kreb's cycle responsible for ATP production using dog kidney and liver tissues.
Effort was made to explore the protective effects of calcium supplements on the dehydrogenases to prevent severe toxicities associated with CDDP treatment. 
MATERIALS AND METHODS

RESULTS
Effects of Various Treatments on Dehydrogenases:
Histochemically, of all the dehydrogenases studied (MDH, SDH, GDH, I-HBDH, IDH and G-6-PDH), only G-6-PDH demonstrated an increase after CDDP, treatment (see Table I ). Thus, for the sake of simplicity, only MDH, and G-6-PDH will be discussed in detail here.
Sections of normal kidney and liver tissues, incubated for MDH localization demonstrated a dark blue granulation with intense diffuse staining throughout the cytoplasm of the cells. In the normal kidney, staining intensity and localization was approximately the same in both the cortical and medullar regions with the proximal and distal tubules having equally pronounced enzyme localization. For the sake of uniformity most of the observations described here are restricted to the pericentral regions of the liver.
In CDDP treated tissues, MDH staining was significantly decreased compared to normal. However, in ergocalciferol plus Tums 500 pretreated animal tissues, MDH staining and localization were very similar to that of the normal tissues. Post-treatment of the CDDP treated animals with ergocalciferol and Tums 500 did not show any protective effects of calcium (Table I) .
Sections of normal tissues stained for G-6-PDH localization demonstrated a diffuse staining throughout the cytoplasm. However, after CDDP treatments, G-6-PDH staining was much more enhanced compared to the normal tissues with the exception of ergocalciferol/calcium plus CDDP treatment where the G-6-PDH levels were similar to the normal tissues. Again, ergocalciferol and Tums 500 administration after CDDP treatment did not show any deviations from that of the CDDP treatment alone (Table I) .
Effects of Various Treatments on Non-specific Lipase Activity:
Under the light microscope non-specific lipase activity was observed as brown diffuse granulation throughout the tissues. In the kidneys, staining was similar in the proximal and distal tubules of the cortex and medulla. CDDP treatment caused an elevation in lipase throughout the kidney tubules and the hepatocytes as compared to the normal. After calcium pretreatment followed by CDDP the level of lipase was close to that of the normal tissues. It is these hydrolyzed forms of CDDP (diol) that have been shown to be 1000 times more reactive than CDDP, and act through the inhibition of mitochondrial respiration by inducing uncoupling of oxidative phosphorylation. 6 This results in an efflux of calcium from the mitochondria and a temporary increase in the cellular calcium levels, which is thought to play a significant role in the disruption of normal calcium homeostasis, and hence cell function. In vitro studies have demonstrated that the energy requiring calcium transport in the mitochondria can be measured by the increased oxygen consumption after diol. This oxygen consumption is directly proportional to the concentration of diol used and can be reversed by SH rich N-acetyI-L-cysteine (NAC).
z CDDP in an unhydrolyzed state does not seem to have any effect.
Mitochondrial glutathione (GSH) seems to be essential in the regulation of inner mitochondrial permeability and enzyme function by keeping SH in the reduced state. When the SH-groups of enzymes are not maintained in a reduced form, they become inactivated. CDDPinduced toxicities, especially nephrotoxicity, seem to be related to a decrease in the intracellular 20, 21 concentrations of GSH and protein bound SH-groups.
NADH, which helps to maintain SH groups, declines with CDDP treatment. Consequently, this depletion of GSH and NADH appears to result in the inhibition of some dehydrogenases, resulting in the uncoupling of oxidative phosphorylation leading to hydroxyl 17 22 radical formation and oxidative stress.
These free radicals attack polyunsaturated lipids and proteins and initiate lipid peroxidation.
This process becomes autolytic and causes severe damage to membrane integrity.
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Hypermetabolism is a cellular means of compensation for increased energy needs as a result of mitochondrial damage but this also leads to the additional activation of unregulated Ca =+- 
